Vestibular Schwannoma Management

VS 101 - Cerebellopontine Culprit

• Benign tumor from Schwann cells of CN VIII; most common cerebellopontine angle (CPA) mass.
• Origin: Typically inferior vestibular nerve > superior.
• Genetics: NF2 gene mutation (Merlin protein) on chromosome 22q12.
  • Bilateral VS is pathognomonic for Neurofibromatosis Type 2 (NF2).
• Growth: Slow, average 1-2 mm/year. 📌 Very Slow.

⭐ Progressive, unilateral sensorineural hearing loss (SNHL) is the hallmark symptom.

Symptoms & Signs - Hearing Hijinks

• Unilateral/Asymmetric Sensorineural Hearing Loss (SNHL): Hallmark symptom (90-95%).
  • Typically progressive, insidious onset; initially affects high frequencies.
  • Sudden SNHL can occur in ~10-15% of patients.
• Unilateral Tinnitus: Common (70%); often first symptom, may precede SNHL. Can be ringing, buzzing.
• Poor Speech Discrimination: Disproportionately worse than pure tone audiometry (PTA) findings.

  ⭐ Rollover phenomenon: Speech discrimination scores significantly decrease at higher sound intensities, a classic sign.

• Aural fullness: Sensation of pressure or blockage in the ear.

Diagnosis Decoded - Scan Secrets

• MRI with Gadolinium (Gd) contrast: Gold standard investigation.
  • T1-weighted + Gd: Shows intensely enhancing lesion.
  • T2-weighted: Tumor hyperintense; delineates Internal Auditory Canal (IAC)/Cerebellopontine Angle (CPA) anatomy.
• Hallmark Sign:
  • "Ice Cream Cone" Appearance: Tumor in CPA extending into a widened IAC.
• Other Modalities:
  • CT (Bone window): Shows IAC widening if MRI is unavailable/contraindicated.
  • Audiometry: Asymmetric Sensorineural Hearing Loss (SNHL) is the key clinical finding prompting imaging.

⭐ Bilateral vestibular schwannomas are diagnostic of Neurofibromatosis Type 2 (NF2).

Management Modalities - Treatment Triangle

Core strategies for Vestibular Schwannoma (VS) involve a "treatment triangle":

• Observation (Watchful Waiting/Active Surveillance):
  • Serial MRI for small, asymptomatic/mildly symptomatic tumors.
  • Often for elderly or comorbid patients.
• Microsurgery:
  • Goal: Tumor removal, facial/cochlear nerve preservation.
  • Approaches: Translabyrinthine, Retrosigmoid, Middle Cranial Fossa (MCF).
  • Indicated for larger tumors, significant symptoms, or younger patients.
• Radiosurgery/Radiotherapy (SRS/SRT):
  • E.g., Gamma Knife, CyberKnife.
  • Goal: Arrest tumor growth, preserve function.
  • For smaller tumors (<3 cm), growing tumors, or poor surgical candidates.

⭐ > For VS <3 cm, SRS offers high tumor control rates with functional preservation.

Surgical Strikes & Radio Rays - Scalpels & Beams

• Surgery: Max safe removal; preserve CN VII, hearing.
  • Approaches:
    • Translabyrinthine (TL): Sacrifices hearing. Large tumors / poor hearing. Good CN VII access.
    • Retrosigmoid (RS): Hearing preservation possible. CPA tumors ± IAC extension.
    • Middle Cranial Fossa (MCF): Best hearing preservation. Small (<1.5 cm) intracanalicular tumors.
  • IONM essential for CN VII.
• Stereotactic Radiosurgery (SRS): e.g., Gamma Knife.
  • Tumors <3 cm (ideal <2.5 cm), elderly, unfit, patient choice.
  • Goal: Growth arrest (control). Dose: 12-13 Gy (marginal).
  • Non-invasive. Tumor remains. Risks: delayed CN palsies, ↓hearing.

⭐ Gross total resection (GTR) is aimed for, but subtotal resection (STR) followed by SRS is an option to preserve facial nerve function.

High‑Yield Points - ⚡ Biggest Takeaways

• Vestibular Schwannoma (VS) is the most common Cerebellopontine Angle (CPA) tumor, arising from Schwann cells of CN VIII.
• Progressive unilateral sensorineural hearing loss (SNHL) and tinnitus are classic early symptoms.
• MRI with gadolinium contrast is the gold standard diagnostic test.
• Management options include observation (for small/asymptomatic tumors), microsurgical excision, and stereotactic radiosurgery (SRS).
• Preservation of facial nerve (CN VII) function is a primary surgical goal.
• Bilateral vestibular schwannomas are pathognomonic for Neurofibromatosis Type 2 (NF2).